# Epitalon: research overview > Epitalon: research overview — yolopeptide — A cited literature summary of epitalon (AEDG), the lead compound among these Longevity & Cellular Health research peptides: telomerase and melatonin mechanisms, the mouse lifespan result, the single-lineage problem, and community reports labelled as anecdote. **02 — SYNTHETIC PINEAL TETRAPEPTIDE** Four amino acids, a survival-curve result in mice, a telomerase result in human cells, and an evidence base that leans harder on one research lineage than any other compound on this desk. ## The short version Epitalon is a peptide of only four amino acids — alanine, glutamic acid, aspartic acid, glycine, which is why it is also written AEDG. It was designed to reproduce, in a single defined molecule, the amino-acid composition of epithalamin: a crude extract of the pineal gland, the structure that governs the melatonin rhythm. Two claims travel with it. The first is that it switches telomerase back on. Telomerase is the enzyme that rebuilds telomeres, the protective caps on the ends of chromosomes that shorten each time a cell divides; adult cells mostly keep it switched off. In cultured human cells, adding epitalon restored that activity and lengthened telomeres [9][7]. The second is that it nudges the melatonin machinery in pineal cells, which has been shown in rat cell culture [8]. There is one animal survival result, in mice, and it is more specific than the headlines suggest [11]. There is one long human study, and it was observational and used the crude extract rather than this molecule [10]. Most of the foundation was built by a single research group, and that matters more than any single number below. ## What it is Epitalon is the linear tetrapeptide H-Ala-Glu-Asp-Gly-OH, a synthetic molecule derived from the amino-acid composition of epithalamin, a polypeptide extract of the bovine pineal gland. It appears in the literature as epithalon, epithalone, the AEDG peptide, the AEDG tetrapeptide, or simply Ala-Glu-Asp-Gly. One naming distinction is worth holding onto, because it is the most common error in material written about this compound. **Epithalamin is the bovine pineal extract; epitalon is the synthetic tetrapeptide.** They are legally and chemically distinct, and their evidence bases are distinct too — including the single longest human study, which used the extract [10]. Marketing copy routinely merges the two records into one. This desk does not. Its classification here is a synthetic regulatory peptide studied as a geroprotector, for research use. It has no FDA, EMA or MHRA approval, no registered indication, and no approved human formulation. ## How it works Two proposed axes converge, and a third is hypothesised. **Telomere maintenance.** Epitalon is proposed to upregulate hTERT, the catalytic subunit of telomerase, restoring telomerase activity in somatic cells and extending telomere length in culture [9][7]. In a normal adult cell that machinery is largely dormant, so this is a reactivation rather than an amplification. **The pineal melatonin axis.** In pinealocytes, epitalon stimulates AANAT — the rate-limiting enzyme of melatonin synthesis — and its transcription factor pCREB, raising melatonin output [8]. The framing offered for this is normalisation of an age-related neuroendocrine and circadian drift rather than supplementation of a hormone. **A hypothesised epigenetic component.** The AEDG sequence is proposed to bind histone H1 subtypes and specific DNA motifs, associated with decondensation of the chromatin that tightens in aged cells. This is a hypothesis carried in the review literature, not a demonstrated mechanism. The mechanistic detail across all three axes comes overwhelmingly from in vitro and animal work, and a 2025 review is explicit that physico-chemical and structural characterisation of the peptide itself remains limited and that it is uncertain whether the described mechanisms are the only ones operating [6]. Its named targets are telomere maintenance and replicative lifespan, pineal melatonin synthesis and circadian rhythm, the neuroendocrine ageing axis, oxidative stress and mitochondrial function in oocyte and retinal models, and age-related chromatin condensation. ## What the research shows **Human cell lines, 2025.** Epitalon at 0.1 to 1 microgram per millilitre extended telomere length in normal human cells — fibroblasts and mammary epithelial cells — through hTERT upregulation and telomerase activation, in a dose-dependent fashion. In breast-cancer cell lines, telomere extension occurred largely through a different route, Alternative Lengthening of Telomeres, which was significant in the cancer lines and only minor in normal ones [7]. This is the most recent and most independent replication of the original telomere claim, and it did not arrive alone. **Human somatic cells, 2003.** Adding the peptide to telomerase-negative human fetal fibroblast cultures induced expression of the catalytic telomerase subunit, telomerase enzymatic activity, and telomere elongation in cells that had none to begin with [9]. This is the foundational result the compound is known for. **Rat pinealocyte culture, 2012.** Epitalon stimulated AANAT and pCREB synthesis and raised melatonin levels in the culture medium; co-administration with norepinephrine potentiated the AANAT and pCREB response [8]. **Mouse lifespan, 2003.** In female outbred Swiss-derived SHR mice given 1.0 microgram per mouse subcutaneously on five days a month from three months of age, maximum lifespan increased 12.3% and survival of the last 10% of the cohort increased 13.3%. Chromosome aberrations in bone marrow fell 17.1%. Leukaemia was inhibited 6.0-fold while total tumour incidence was unchanged. **Mean lifespan was unchanged** [11]. **Mouse oocytes, 2022.** At 0.1 mM in vitro, epitalon protected oocytes against post-ovulatory ageing by reducing reactive oxygen species and modulating mitochondrial activity, with quality preserved at 6, 12 and 24 hours [12]. **Human cohort, 2003.** Over six to eight years, 266 elderly people receiving the pineal peptide preparation Epithalamin — alone, and in combination with the thymic preparation thymalin — showed lower mortality than untreated controls: a 1.6- to 1.8-fold decrease for the pineal preparation alone, and a 4.1-fold decrease for the combination given annually over six years [10]. The study was observational, with neither randomisation nor a placebo arm, and it used the extract rather than synthetic epitalon. **Review, 2025.** A recent overview characterises epitalon as a geroprotective AEDG tetrapeptide with antioxidant, neuroprotective and antimutagenic properties acting through melatonin synthesis, IL-2 messenger RNA, thymocyte mitogenic activity and telomerase — while stating that it remains uncertain whether these are its only mechanisms of action [6]. ## Reported effects, cautions & safety What follows is what people in longevity and self-experimentation communities report about epitalon. It is **anecdotal, not clinical evidence**: uncontrolled, unblinded, unverified self-report, collected without measurement and subject to expectation. No dose or schedule is given here, and none should be inferred. The most frequently reported subjective effect is better and deeper sleep, with a faster time to fall asleep — described as more solid, more restorative rest. Close behind it is a sense of a normalised day-night rhythm, less of a jet-lagged grogginess on waking, which is at least consistent with the melatonin framing above but is not a measured outcome. A subset describe more daytime energy and less fatigue, which could as easily follow from the sleep reports as from anything pharmacological. Vaguer impressions recur too: a general lift in well-being or "feeling younger", occasional reports of skin looking fresher or hair and nails feeling stronger, and a calmer baseline with less stress reactivity. None of these is tied to a verified biomarker change, and in uncontrolled reports none is distinguishable from placebo. The counterweight is important and is reported just as often: **many people report no noticeable effect whatsoever**, during or after a cycle. That outcome is consistent with the state of the controlled evidence and it is systematically underrepresented in promotional material. Physical complaints are mostly the ordinary ones of self-injection — redness, soreness and small bruising at the injection site, described as minor and transient. A minority report transient drowsiness or unusually vivid dreams, loosely attributed to the melatonin framing and inconsistent across reports; mild headache or lightheadedness is occasionally mentioned early on and is not established as caused by the peptide. Two recurring themes are not drug effects at all: experienced community members and some clinicians repeatedly caution that research-grade material is unregulated and what is in a vial is uncertain, and a common reflective report is disappointment that the headline telomere and anti-ageing promises rest on animal and laboratory work and cannot be observed in oneself at any price. The documented cautions are these. **Investigational, not approved.** Epitalon has no approval in major Western markets and no registered indication, so it has never cleared the safety, purity and efficacy review that regulated medicines undergo [6]. **A single research lineage.** Most foundational claims, including the original human-cell telomerase result, come from Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology [9]. Findings that are not independently reproduced may not generalise, and the headline anti-ageing claims should be treated as unproven. **Observational human data only.** The most-cited human result — the six-to-eight-year cohort of 266 elderly subjects — lacked randomisation and a placebo arm by Western standards, so reported benefits cannot be separated from selection, expectation and other confounders, and the safety picture is correspondingly weak [10]. **A theoretical telomerase-and-cancer concern.** Telomerase reactivation extends replicative lifespan in normal cells, but telomerase activity is also a hallmark of most cancers, and the 2025 study found epitalon raising telomere length in breast-cancer lines through Alternative Lengthening of Telomeres [7]. The long-term oncological implications of activating these pathways in humans are unresolved. **No long-term human safety data and no human pharmacokinetics.** There are no randomised long-term trials and no published human pharmacokinetic study; the frequently quoted half-life of minutes is an inference from short-peptide chemistry, not a measured value. The absence of reported adverse events in small studies is not the same thing as controlled long-term safety [6]. **Anti-tumour signals come from narrow models.** Reports that epitalon reduced tumours used induced or genetically engineered cancer models, such as a chemically induced colon-carcinogenesis study in rats. These are specific experimental settings and do not amount to general oncological safety surveillance in humans. ## Where it fits in the healthspan question Epitalon is the lifespan-side compound on this desk, and its own best experiment is the sharpest argument for keeping lifespan and healthspan apart. In the SHR mice, maximum lifespan rose 12.3% while mean lifespan did not move [11]. A treatment that lengthens the tail without shifting the middle has not made the average animal's life longer; it has changed what happens at the extreme of the distribution. Two further numbers from the same study point in the healthspan direction instead: chromosome aberrations in bone marrow fell 17.1%, and leukaemia was inhibited 6.0-fold — while total tumour incidence stayed flat [11]. That combination reads as a shift in the *kind* of pathology, not the abolition of it. The human record inverts the usual worry. Its endpoint is the one that matters most — mortality over six to eight years — and its method is the one that supports it least, being observational, unrandomised, unblinded, and conducted with the parent extract rather than the synthetic peptide [10]. A strong endpoint measured weakly does not become strong evidence by being about death. Everything else in the epitalon file is a cellular surrogate: telomerase and telomere length in culture [9][7], melatonin enzymes in pinealocytes [8], reactive oxygen species and mitochondrial activity in oocytes [12]. These describe mechanisms that *could* underwrite either clock. None of them measures either one. The honest summary is that epitalon has the better story and the weaker method, and that its single-lineage problem is not a footnote to that story but part of its structure. The 2025 human cell-line replication is genuinely important for exactly this reason — and it arrived carrying a cancer-line finding that the original account did not include [7]. --- A reference desk for the ageing-and-cellular-health literature: every figure here traces to a listed study, and none of it is a clinic, a vendor, or a protocol.